Japan-based Astellas Pharma Inc. (TYO: 4503) has announced its financial results for the first quarter of the fiscal year 2024, ending June 30, 2024. The company reported a robust performance with a 26.2% increase in global sales, reaching JPY 473,124 million (USD 3.16 billion) compared to the same period last year. The growth was driven by strong sales across its core portfolio, including prostate cancer drug Xtandi (enzalutamide), which saw a 28.8% increase, and the antibody-drug conjugate (ADC) bladder cancer therapy Padcev (enfortumab vedotin), with a remarkable 152.3% growth. The company’s press release also noted a 32.8% increase in sales for the acute myeloid leukemia drug Xospata (gilteritinib). The weakening of the Japanese yen contributed positively to revenues, adding JPY 45.4 billion (USD 303 million) and increasing operating profits by JPY 11.6 billion (USD 77.5 million).- Flcube.com
Recent news:
-
Sino Biopharmaceutical Submits NDA for Anlotinib and Penpulimab Combo in HCC to NMPA -
Sihuan Pharmaceutical's Huisheng Pharm Strikes Exclusive Deal for Semaglutide Biosimilar in China -
Innovent Biologics' IBI354 Earns Breakthrough Therapy Designation for Ovarian Cancer Treatment -
CDE Includes Double-Crane's Hydroxocobalamine and Sanofi Genzyme's Fitusiran in Rare Disease Care Plan -
Apeiron Therapeutics Initiates Phase Ia/B Study for GTA182 in Solid Tumors with MTAP Deficiency
